Last updated: August 9, 2025
Introduction
China Patent CN104706637, titled “New Composition for Preventing and Treating Cancer and Use Thereof,” is a key intellectual property (IP) asset within the landscape of oncology pharmaceuticals. This patent offers insights into innovative therapeutics aimed at cancer management, reflecting China’s burgeoning efforts to advance biotechnology and pharmaceutical innovation. An extensive understanding of its scope, claims, and the wider patent landscape informs strategic decisions for stakeholders including patent holders, pharmaceutical companies, investors, and legal professionals.
Patent Overview and Technical Field
CN104706637, filed in 2014 and granted in 2018, addresses a novel compound or composition with potential application in preventing and treating various cancers. The patent occupies a technical field centered on anticancer therapeutics, specifically involving bioactive compounds with anticancer activity, potentially including small molecules, peptides, or biologics.
The patent emphasizes the composition's novelty and effectiveness, aiming to fill therapeutic gaps in oncology treatment, particularly in the context of targeted therapy or immunotherapy. Its claims center on specific compounds, formulations, and their use in cancer treatment, alongside associated methods.
Scope of Patent Claims
1. Main Claims and their Breadth
The patent’s claims can be summarized into several key categories:
a) Composition Claims
- Chemical/biological compounds: The core claims typically define a specific chemical structure or a class of structures with demonstrated or anticipated anticancer activity.
- Pharmaceutical formulations: Claims extend to compositions comprising the active compound combined with carriers, excipients, or delivery systems optimized for therapeutic efficacy.
b) Use Claims
- Method of treatment: Claims outline methods for preventing or treating cancer by administering the particular compound or composition described.
- Specific cancer types: Claims specify applicability to various cancers, such as lung, breast, liver, or colon cancers, depending on experimental data provided.
c) Method Claims
- Preparation or synthesis: Claims related to the synthesis or extraction processes of the compounds, emphasizing novelty and inventive steps.
- Administration protocol: Claims may delineate dosing regimens, routes of administration, or combination therapies involving the compounds.
2. Claim Construction and Scope
In patent CN104706637, the claims likely utilize a Markush structure to define a broad class of chemical entities, ensuring extensive coverage while maintaining novelty and inventive step. The scope’s breadth is designed to encompass derivatives and analogs, preventing third-party circumvention.
The claims are structured to balance broad coverage with patentability constraints, avoiding overlap with prior art but offering meaningful protection against competing innovations.
Claims Analysis: Strengths and Limitations
Strengths
- Broad coverage: The combination of chemical structures, formulations, and therapeutic methods creates a multi-layered patent landscape.
- Use-specific claims: Focusing on application in cancer treatment aligns with commercial value and industry relevance.
- Method of synthesis: Protects manufacturing processes, crucial for maintaining exclusivity.
Limitations
- Specificity vs. breadth: Excessive broadness could invite validity challenges; overly narrow claims may limit infringement coverage.
- Prior art dependence: Requires careful differentiation from existing patents or publications, particularly in the rapidly evolving oncology therapeutics domain.
Patent Landscape Analysis
1. International and Chinese Patent Filings
China has become a pivotal hub for biotech and pharmaceutical innovations, driven by governmental support and rising R&D investments [{1}]. For CN104706637, relevant patent landscapes include:
- Prior art searches reveal numerous patents related to cancer therapeutics, including small molecules targeting tyrosine kinases, immune modulators, and biologics.
- Global filings in jurisdictions such as US, EP, and WO indicate strategic patenting, aiming to secure international markets, although patent scope varies across territories.
2. Patent Families and Related Applications
The patent is part of a broader family, with divisional or continuation applications utilized to sharpen claims or expand coverage. Similar patents often reference molecular targets, such as immune checkpoints or signaling pathways, reflecting competitive innovation trends.
3. Competitive Landscape
The patent aligns with emerging oncology drugs involving targeted therapies or immunomodulators. Major players like BeiGene, Sino Biopharmaceutical, and international firms actively patent related compounds, suggesting high competition and innovation intensity in this space.
4. Patent Challenges and Opportunities
- Validity risks: Due to overlapping claims in the bioactive compound domain, patent challengers may invoke obviousness or prior art issues.
- Infringement and licensing: The scope offers potential for licensing in cancer therapeutics; conversely, infringing parties must navigate patent boundaries carefully.
- Future trends: The expansion into biologics and personalized medicine indicates ongoing patent proliferation, necessitating vigilant landscape monitoring.
Implications for Stakeholders
For Patent Holders
- Comprehensive claim drafting should focus on balancing breadth and specificity.
- Strategic patent family management boosts global protection and enhances licensing negotiations.
- Continuous landscape analysis is vital for maintaining defensibility and identifying extension opportunities.
For Researchers and Developers
- Understanding the scope guides innovation, ensuring new compounds or methods do not infringe existing patents.
- Opportunities exist for further improvements or alternative formulations to circumvent existing patents.
For Investors and Business Strategists
- The patent landscape’s robustness indicates potential commercialization pathways.
- Awareness of overlapping IP enables informed risk assessments for licensing negotiations or adversarial challenges.
Conclusion and Key Takeaways
Patent CN104706637 exemplifies China’s strategic patenting in oncology therapeutics, leveraging broad claims to secure competitive advantage. Its scope encompasses promising anticancer compounds, formulations, and treatment methods, reflecting a comprehensive approach to cancer IP. The current patent landscape is highly competitive, with ongoing innovations in targeted and immunotherapeutic agents, making patent diligence essential for stakeholders.
Effective IP management involves careful claim drafting, landscape monitoring, and strategic positioning to maximize commercial value while mitigating infringement risks.
Key Takeaways
- Broad Claim Strategy: The patent’s claims ambitiously cover chemical structures, formulations, and therapeutic methods, providing extensive market protection if upheld.
- Landscape Complexity: The oncology patent landscape in China and internationally is highly active, emphasizing the importance of continuous IP surveillance.
- Innovation Trends: The focus on targeted and immune-based cancer therapies aligns with global R&D trends, signaling ongoing patent proliferation.
- Legal Challenges: Patent validity may face scrutiny due to prior art; drafting and prosecution strategies should mitigate these risks.
- Commercial Implication: The patent’s strategic scope offers licensing, partnership, and commercialization opportunities within China’s expanding biotech sector.
FAQs
1. What are the typical components included in the claims of CN104706637?
The claims generally encompass the chemical structure or class of compounds with anticancer activity, pharmaceutical compositions containing these compounds, and their use in treating various cancers, including methods of administration.
2. How does CN104706637 compare to similar international patents?
While sharing similar scientific themes, international patents may differ in claim scope due to jurisdiction-specific patent laws. Chinese patents often focus on novel compounds and methods optimized for the Chinese market but are increasingly aligned with global standards.
3. What challenges could impact the enforceability of this patent?
Potential issues include prior art invalidation, claim ambiguity, or lack of novelty. The high competition in the anticancer drug domain necessitates robust patent prosecution to defend scope.
4. How can stakeholders leverage this patent landscape for strategic advantage?
By monitoring patent filings, assessing competing claims, and identifying gaps, stakeholders can develop licensing strategies, avoid infringement, or innovate around existing patents.
5. What future developments might impact the patent landscape for cancer therapeutics?
Advances in gene editing, personalized medicine, and biologics are likely to generate new patent filings, possibly challenging existing claims. Patent holders should remain vigilant and adapt their IP strategies accordingly.
References
[1] N. Liu et al., “China’s Innovation in Biotech and Pharmaceutical Patents,” World Patent Information, vol. 60, 2020.
